Journal
HAEMOPHILIA
Volume 20, Issue 4, Pages e243-e250Publisher
WILEY
DOI: 10.1111/hae.12456
Keywords
aPCC; bypassing agents; haemophilia A; immune tolerance induction; inhibitors; rFVIIa
Categories
Funding
- Bayer
- Biotest
- Novo Nordisk
Ask authors/readers for more resources
Haemophilia A (HA) patients with high responding inhibitors require therapies with bypassing agents to control bleedings or Immune Tolerance Induction (ITI) to attempt inhibitor eradication and restore FVIII therapy. The aim of this study was to assess the therapeutic management and product consumption of HA inhibitor patients and the relative costs in Italy. A retrospective survey was performed utilizing data from the National Registry of Congenital Coagulopathies and from a specific questionnaire on product consumption of HA inhibitor patients over the year 2011. Among HA patients, 10% had currently detectable inhibitors; 24% of patients were undergoing ITI (mostly children) and 76% utilized bypassing agents. Patients on ITI consumed 45000000IU of FVIII (median consumption/patient of 1200000IUyear-1). Patients receiving bypassing agents utilized 21000000IU of aPCC (median consumption/patient of 360000IUyear-1), and 38000mg of rFVIIa (median consumption/patient of 440mgyear-1). The annual cost/patient on ITI and on bypassing agents therapy was analysed. Recombinant products represen-ted the product of choice for children therapies in >90% of the cases. FVIII prophylaxis of severe HA patients without inhibitor costs about half than therapy with bypassing agents and is three times less expensive than prophylaxis with such agents. Therefore, the possibility to restore FVIII prophylaxis, having eradicated the inhibitor through ITI, can justify the high costs of ITI treatment needed in the short term. Consistent with this notion, over the last years a 50% increase in the number of patients undergoing ITI in Italy was registered.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available